A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Acadia Healthcare Company, Inc. ACHC
Weak broader-coverage candidate · Acadia Healthcare Company, Inc.
On FrontierLab's discovery record since 2026-07-16 (11 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-10-03), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 4.3% |
|---|---|
| Gross margin | 35.6% |
| Gross profits / assets | 0.22 |
| Rule of 40 | 14.4 |
| Net margin | 10.1% |
| Cash runway (months) | — |
| PEG | — |
| Price / sales | 0.8 |
Quality checklist
- ✗ Revenue growth — 4.3% (pass ≥ 20%)
- ~ Gross profits / assets — 0.22 (pass ≥ 0.33)
- ✗ Gross margin — 35.6% (pass ≥ 60%)
- ✓ Cash generation
- ~ Share dilution — 1%
Fundamentals — snapshot as of 2026-10-03
| Stage | Established |
|---|---|
| Share issuance (YoY) | 1% · modest issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-12.45 |
| Burn multiple | — |
| Gross-margin trend (pts) | -45.6 |
| Cash / assets | 0.03 |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-07-28 |
Momentum context — a snapshot from 2026-10-03, not current
| Price at surface | $28.06 (as of 2026-10-03) |
|---|---|
| 52-week range | $11.43 – $35.83 |
| % off 52-wk high | -21.7% |
| RSI (14) | 48 |
| Relative volume | 1× |
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-10-03 (end-of-day). How grades are computed →